[go: up one dir, main page]

AU2001286514A1 - Diagnosis and treatment of tumor-suppressor associated disorders - Google Patents

Diagnosis and treatment of tumor-suppressor associated disorders

Info

Publication number
AU2001286514A1
AU2001286514A1 AU2001286514A AU8651401A AU2001286514A1 AU 2001286514 A1 AU2001286514 A1 AU 2001286514A1 AU 2001286514 A AU2001286514 A AU 2001286514A AU 8651401 A AU8651401 A AU 8651401A AU 2001286514 A1 AU2001286514 A1 AU 2001286514A1
Authority
AU
Australia
Prior art keywords
tslc1
expression
disorder
proliferating
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001286514A
Inventor
Yoshinori Murakami
Roger Harper Reeves
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2001286514A1 publication Critical patent/AU2001286514A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Methods are provided for detecting a cell proliferative disorder associated with TSLC1 by contacting a proliferating cell of a subject suspected of having the disorder with a reagent that detects TSLC1 and detecting the level of TSLC1 in the proliferating cell. TSLC1 is a single gene whose expression is reduced or absent in A549 and some other NSCLC, hepatocellular carcinoma and pancreatic cancer cell lines. It has further been discovered that TSLC1 expression or suppression is perfectly correlated with promoter methylation state. Restoration of TSLC1 expression to normal or higher levels is sufficient by itself to suppress tumor formation. The invention further provides methods of treating such disorders by contacting cells of a patient suffering from the disorder with a therapeutically effective amount of a reagent that modulates TSLC1 level in the proliferating cells.
AU2001286514A 2000-08-15 2001-08-15 Diagnosis and treatment of tumor-suppressor associated disorders Abandoned AU2001286514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22526400P 2000-08-15 2000-08-15
US60225264 2000-08-15
PCT/US2001/025690 WO2002014557A1 (en) 2000-08-15 2001-08-15 Diagnosis and treatment of tumor-suppressor associated disorders

Publications (1)

Publication Number Publication Date
AU2001286514A1 true AU2001286514A1 (en) 2002-02-25

Family

ID=22844210

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001286514A Abandoned AU2001286514A1 (en) 2000-08-15 2001-08-15 Diagnosis and treatment of tumor-suppressor associated disorders

Country Status (7)

Country Link
US (3) US6596493B1 (en)
EP (1) EP1339871B1 (en)
AT (1) ATE411037T1 (en)
AU (1) AU2001286514A1 (en)
CA (1) CA2419529C (en)
DE (1) DE60136212D1 (en)
WO (1) WO2002014557A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002014557A1 (en) * 2000-08-15 2002-02-21 The Johns Hopkins University School Of Medecine Diagnosis and treatment of tumor-suppressor associated disorders
EP1464709B1 (en) 2003-03-31 2007-12-26 Stichting Researchfonds Pathologie Detection of HPV-induced invasive cancers and their precursor lesions with invasive potential
JP2007500132A (en) * 2003-07-25 2007-01-11 アムジェン インコーポレイテッド LDCAM antagonists and agonists and methods of use thereof
US8048992B2 (en) * 2005-02-28 2011-11-01 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
WO2008026010A1 (en) * 2006-08-29 2008-03-06 Oxford Genome Sciences (Uk) Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
CN101153336B (en) * 2006-09-27 2011-09-07 香港中文大学 method and kit for detecting DNA methylation degree
US9102948B2 (en) 2006-11-17 2015-08-11 22Nd Century Limited, Llc Regulating alkaloids
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
US20110159499A1 (en) * 2009-11-25 2011-06-30 Quantalife, Inc. Methods and compositions for detecting genetic material
AU2010221186B2 (en) * 2009-03-05 2013-08-22 E. R. Squibb & Sons, L.L.C. Fully human antibodies specific to CADM1
CN103562407A (en) 2011-02-09 2014-02-05 伯乐生命医学产品有限公司 Analysis of nucleic acids
WO2013163428A1 (en) * 2012-04-25 2013-10-31 The Regents Of The University Of Colorado Detection of ret fusions in cancer
JP7190165B2 (en) * 2018-04-13 2022-12-15 学校法人近畿大学 Method for determination of possibility of suffering from chronic kidney disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552277A (en) 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
US5856094A (en) 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
WO1998056952A1 (en) 1997-06-09 1998-12-17 University Of Southern California A cancer diagnostic method based upon dna methylation differences
IL140937A0 (en) * 1998-08-07 2002-02-10 Immunex Corp Molecules designated ldcam
AU1231400A (en) * 1998-10-28 2000-06-05 Human Genome Sciences, Inc. 12 human secreted proteins
CA2349815A1 (en) * 1998-11-12 2000-05-18 Incyte Pharmaceuticals, Inc. Human cell surface receptor proteins
WO2002014557A1 (en) * 2000-08-15 2002-02-21 The Johns Hopkins University School Of Medecine Diagnosis and treatment of tumor-suppressor associated disorders

Also Published As

Publication number Publication date
US6596493B1 (en) 2003-07-22
DE60136212D1 (en) 2008-11-27
CA2419529C (en) 2013-02-12
EP1339871A4 (en) 2005-08-17
WO2002014557A1 (en) 2002-02-21
ATE411037T1 (en) 2008-10-15
US20070072224A1 (en) 2007-03-29
US7833712B2 (en) 2010-11-16
US7153657B2 (en) 2006-12-26
EP1339871A1 (en) 2003-09-03
US20030165974A1 (en) 2003-09-04
EP1339871B1 (en) 2008-10-15
CA2419529A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
AU2001286514A1 (en) Diagnosis and treatment of tumor-suppressor associated disorders
Gil‐Martín et al. The emergence of melatonin in oncology: Focus on colorectal cancer
Lai et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity
Takenoue et al. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method
Lin et al. Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9
Takata et al. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma
Clere et al. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
WO2005013800A3 (en) Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
NO970039D0 (en) Method of Inhibiting Cancer Matastases by Oral Administration of Soluble Modified Citrus Pectin
Guo et al. Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2007092414A3 (en) Use of phosphatases to treat tumors overexpressing n-cor
Megova et al. Isocitrate dehydrogenase 1 and 2 mutations in gliomas
Chang et al. PADI3 induces cell cycle arrest via the Sirt2/AKT/p21 pathway and acts as a tumor suppressor gene in colon cancer
Okawa et al. Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2
Xia et al. The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
Furukawa et al. PRIMA‐1 induces p53‐mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation
Marcé et al. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy
Okumura et al. Fragile gene product, Fhit, in oxidative and replicative stress responses
Flitney et al. Antitumor actions of ruthenium (III)-based nitric oxide scavengers and nitric oxide synthase inhibitors
Meng et al. Promoter methylation regulates cigarette smoke‐stimulated cyclooxygenase‐2 expression in esophageal squamous cell carcinoma
WO2006053201A3 (en) Treatment of cancer by simultaneous inhibition of b-raf and restoration or mimicry of p16 ink4a activity
Kim et al. Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification